SeaStar Medical Holding Corp (ICU) · Nov 20, 2026 · Other events
Nasdaq deficiency notice — $0.469M equity vs $2.5M minimum
SeaStar Medical received a Nasdaq compliance notice after its equity fell below the minimum, putting financing and continued listing back in focus.
SeaStar Medical is a commercial-stage medical-device company commercializing QUELIMMUNE for critically ill pediatric patients while advancing broader adult applications of its Selective Cytopheretic Device. This is a balance-sheet and listing problem, not a clinical readout. The company’s September 30, 2026 10-Q showed only $469,000 of stockholders’ equity against Nasdaq’s $2.5 million requirement, while cash was $3.989 million and nine-month operating cash use was $9.128 million. The shortfall was therefore already visible in the quarterly filing; what is new is Nasdaq formally opening the compliance process.
The notice increases the urgency of a capital or balance-sheet fix. SeaStar has until January 4, 2027 to submit a compliance plan, and Nasdaq may grant up to 180 additional calendar days if the plan is accepted. 〔0〕 That likely means the company must address the equity deficit through financing, operating improvement, or another corporate action while it is already consuming cash and reporting substantial losses. This is an inference from the equity gap and cash burn, not a stated commitment to any particular transaction.
The immediate delisting risk is limited, but the strategic pressure is real. The notice does not immediately remove the stock from Nasdaq, but rejection of the plan could make the shares subject to delisting, with an appeal available afterward. 〔1〕 〔2〕
Bottom line: The filing does not derail SeaStar’s medical-device program, but it confirms that weak equity and cash burn are now an active Nasdaq compliance issue rather than just a balance-sheet warning. The business story is modestly weakened until the company shows how it will restore equity and fund operations.
Compliance plan due January 4, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!